Literature DB >> 12117455

Are angiotensin converting enzyme inhibitors and angiotensin receptor blockers becoming the treatment of choice in African-Americans?

Andrew Fenves, C Venkata S Ram.   

Abstract

African-American patients constitute a significant and important group who are at high risk for developing hypertension-related complications. The proportion of African-American patients succumbing to or suffering from cardiovascular, renal, and neurologic sequelae is unacceptably high. Therefore, it is extremely crucial to develop appropriate therapeutic strategies for this vital subset of our society. The renin-angiotensin system may play a role in the pathophysiology of hypertension-related diseases, and therefore drugs that block this system, ie, angiotensin converting enzyme inhibitors and angiotensin receptor blockers, may have a special indication for African-American patients. Although these drugs may not be the most efficacious agents in terms of blood pressure reduction, they have a major benefit in offering target organ protection and arresting disease progression in the African-Americans. Hence, contrary to the old notions, drugs blocking the renin-angiotension system have an important place in the management of hypertension and related disorders in African-American patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117455     DOI: 10.1007/s11906-996-0006-y

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  19 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 2.  Diabetes, hypertension, and cardiovascular disease: an update.

Authors:  J R Sowers; M Epstein; E D Frohlich
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

Review 3.  Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence.

Authors:  N M Kaplan
Journal:  Ann Intern Med       Date:  2001-12-18       Impact factor: 25.391

4.  Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension.

Authors:  J B McGill; P A Reilly
Journal:  Clin Cardiol       Date:  2001-01       Impact factor: 2.882

Review 5.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

6.  The effect of enalapril on advanced diabetic nephropathy in African-American females.

Authors:  E D Crook; J Harris; B Oliver; R Taylor
Journal:  Ethn Dis       Date:  2001 Spring-Summer       Impact factor: 1.847

Review 7.  Rationale for angiotensin II receptor blockers in patients with low-renin hypertension.

Authors:  K A Jamerson
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

Review 8.  Angiotensin II subtype 1 receptor blockers and renal function.

Authors:  R Toto
Journal:  Arch Intern Med       Date:  2001-06-25

9.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Authors:  L Y Agodoa; L Appel; G L Bakris; G Beck; J Bourgoignie; J P Briggs; J Charleston; D Cheek; W Cleveland; J G Douglas; M Douglas; D Dowie; M Faulkner; A Gabriel; J Gassman; T Greene; Y Hall; L Hebert; L Hiremath; K Jamerson; C J Johnson; J Kopple; J Kusek; J Lash; J Lea; J B Lewis; M Lipkowitz; S Massry; J Middleton; E R Miller; K Norris; D O'Connor; A Ojo; R A Phillips; V Pogue; M Rahman; O S Randall; S Rostand; G Schulman; W Smith; D Thornley-Brown; C C Tisher; R D Toto; J T Wright; S Xu
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

10.  Salt sensitivity and resistance of blood pressure. Age and race as factors in physiological responses.

Authors:  F C Luft; J Z Miller; C E Grim; N S Fineberg; J C Christian; S A Daugherty; M H Weinberger
Journal:  Hypertension       Date:  1991-01       Impact factor: 10.190

View more
  4 in total

1.  Andrew Zoltan Fenves, MD: a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Andrew Zoltan Fenves
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-07

2.  Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes.

Authors:  Allison B Rosen; Andrew J Karter; Jennifer Y Liu; Joe V Selby; Eric C Schneider
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

Review 3.  Physiology, genetics, and cardiovascular disease: focus on African Americans.

Authors:  Gary H Gibbons
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

4.  Anti-hypertensive medicines prescribing for medical outpatients in a premier teaching hospital in Nigeria: a probable shift of paradigm.

Authors:  Unyime I Eshiet; Kazeem B Yusuff
Journal:  Pharm Pract (Granada)       Date:  2014-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.